Antisense Oligonucleotide (ASO) Walk

NOTICE OF INTENT to Sole Source

1. SOLICITATION NUMBER: 75N95025Q00265

2. TITLE: Integrated DNA Technologies (IDT) Antisense Oligonucleotide (ASO) Walk

3. CLASSIFICATION CODE:

6640 LABORATORY EQUIPMENT AND SUPPLIES

NAICS CODE: 325413 - in-vitro diagnostic substance manufacturing

4. RESPONSE DATE:

September 12, 2025, at 11:59 PM EDT

5. PRIMARY POINT OF CONTACT:

Tiffany Stone

tiffany.stone@nih.gov

Phone: 301.480.7158

6. DESCRIPTION:

INTRODUCTION

THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institutes of Health (NIH) National Institute on Aging (NIA) intends to negotiate on a sole source basis with Integrated DNA Technologies, Inc. to procure antisense oligonuceotides (ASOs) to perform cell-based experiments to identify which of them alter the level of expression of the target gene. IDT DNA Technologies is the established supplier for the ongoing ASO program. Using the same production platform preserves assay comparability, reduces variability, and accelerates translation to animal and pre-clicincal studies. IDT DNA Technologies, Inc can reproduce the exact MOE-gapmer chemistry with identical QC documentation, thereby risking batch effects and schedule delays. IDT offers the only combination of technical compatibility, documented performance, and cost efficiency that meet the project requirements.

NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS

The intended procurement is classified under NAICS code 325413 - in-vitro diagnostic substance manufacturing with a Size Standard of $1,250.

REGULATORY AUTHORITY

This acquisition is for a commercial item or service and is conducted under the authority of the FAR Subpart 13.5 Simplified Procedures for Certain Commercial Products and Commercial Services, U.S.C 41 1901 Simplified acquisition procedures, the statutory authority of 41 USC 3304 Use of noncompetitive procedures.

The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2025-05, with effective date August 7, 2025

This acquisition is conducted under the procedures as prescribed in FAR Part 13 Simplified Acquisition Procedures; and FAR Part 12 Acquisition of Commercial Items and is not expected to exceed the simplified acquisition threshold.

DESCRIPTION OF REQUIREMENT

PURPOSE AND OBJECTIVES:

The Laboratory of Neurogenetics requires 474 custom antisense oligonucleotides to support NIH-funded research on amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These reagents will enable a high-density oligo walk across a newly identified disease gene, allowing systematic down-regulation studies and subsequent efficacy testing in patient-derived iPSC models.

The project aims to enhance our understanding of neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). We will conduct an oligo walk in which we test 474 antisense oligonucleotides (ASOs) arranged in series along a gene that we have recently identified as a cause of ALS and FTD.

Project requirements: Please see the Purchase Description attached to this posting.

ESTIMATED DELIVERY DATE:

Within 20 business days of receipt of sequence file and purchase order

CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION

The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Integrated DNA Technologies, Inc. is the only sole proprietor that can provide the required ASOs compatible with the prior experimental research. Only this suggested source can furnish the agency's requirements, to the exclusion of other sources.

The intended source is:

Integrated DNA Technologies, Inc.

1710 Commercial Park

Coralville, IA 52241

CLOSING STATEMENT

THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice.

A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by the closing date and time of this announcement and must reference the solicitation number, 75N95025Q00265. Responses must be submitted electronically to Tiffany Stone, Contract Specialist, at tiffany.stone@nih.gov and Christine Frate, Contracting Officer, at christine.frate@nih.gov. U.S. Mail and fax responses will not be accepted.